HealthCare Royalty Partners ("HCR") is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCR has raised over $5.9 billion in cumulative capital commitments and has offices in Stamford (CT), San Francisco, Boston and London. The HCR team consists of 36 individuals (including our Senior Advisors), including former pharmaceutical executives, scientists, physicians, bankers, research analysts and consultants.
Our philosophy is simple - We are asset-focused investors seeking to identify compelling investment opportunities that will generate long-term value. We target healthcare assets with significant clinical value and strong barriers to entry that are meaningful to their marketer. We also look for assets that will produce sustainable revenues over an extended period of time. Our investments span the pharmaceutical, biotechnology and specialty pharmaceuticals sectors.
Our investment platform is designed to serve as a long-term capital resource for our partners; flexible and directly aligned with their business models and objectives. Our team utilizes multiple investment approaches to help our partners achieve their goals including: customized debt, royalty monetization, and revenue participation financings. Since 2003, HCR's senior professionals have completed more than 60 healthcare investments.
HealthCare Royalty Partners® is a registered trademark of HealthCare Royalty Management, LLC in the U.S. and a trademark in other countries.
Our philosophy is simple - We are asset-focused investors seeking to identify compelling investment opportunities that will generate long-term value. We target healthcare assets with significant clinical value and strong barriers to entry that are meaningful to their marketer. We also look for assets that will produce sustainable revenues over an extended period of time. Our investments span the pharmaceutical, biotechnology and specialty pharmaceuticals sectors.
Our investment platform is designed to serve as a long-term capital resource for our partners; flexible and directly aligned with their business models and objectives. Our team utilizes multiple investment approaches to help our partners achieve their goals including: customized debt, royalty monetization, and revenue participation financings. Since 2003, HCR's senior professionals have completed more than 60 healthcare investments.
HealthCare Royalty Partners® is a registered trademark of HealthCare Royalty Management, LLC in the U.S. and a trademark in other countries.
Location: United States, Connecticut, Stamford
Employees: 11-50
Founded date: 2007
Mentions in press and media 21
| Date | Title | Description |
| 09.04.2026 | Apnimed Secures $150M for AD109 Launch, Targets Sleep Apnea Market | Apnimed secured pivotal debt financing. Up to $150 million from HealthCare Royalty Partners will fund AD109. This oral drug targets obstructive sleep apnea. It's poised for U.S. commercial launch. The financing comes in tranches. $50 millio... |
| 07.04.2026 | Apnimed: $150 Million Debt Financing Secured To Support AD109 Sleep Apnea Drug Launch | Apnimed has secured up to $150 million in debt financing from HealthCare Royalty Partners to support the planned U.S. commercial launch of its lead product candidate, AD109, an oral treatment for obstructive sleep apnea. The agreement inclu... |
| 06.04.2026 | Apnimed Secures Up to $150M in Debt Financing | Apnimed, Inc., a Cambridge, MA-based pharmaceutical company developing novel oral therapies for obstructive sleep apnea (OSA), entered into a senior secured credit facility for up to $150m with funds managed by HealthCare Royalty Partners. ... |
| 10.11.2025 | KKR’s profit beats forecast on credit-led inflows, one-off charge weighs | KKR co-CEO Joe Bae attends the Global Financial Leaders' Investment Summit, in Hong Kong, Nov. 4, 2025. | Credit: Reuters/Tyrone Siu Investment firm KKR reported a rise in third-quarter profit that beat Wall Street's expectations on Friday,... |
| 26.07.2024 | Fannie Mae and Valinor Pharma: A Tale of Strategic Moves in Finance and Pharma** ** | ** In the bustling world of finance and pharmaceuticals, two recent transactions stand out like beacons in the fog. Fannie Mae, a stalwart in the housing finance sector, has priced its fourth Multifamily Connecticut Avenue Securities (MCAS)... |
| 23.07.2024 | Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million | Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care's commercial platform to grow Movantik ... |
| 08.12.2021 | Kimbell Royalty Partners LP : Closes $57 Million Acquisition of Mineral and Royalty Interests in Cash Transaction - Form 8-K | Kimbell Royalty Partners Closes $57 Million Acquisition of Mineral and Royalty Interests in Cash Transaction Announces Redemption of all Remaining Series A Cumulative Convertible Preferred Units FORT WORTH, Texas, December 7, 2021 - Kimbell... |
| 09.01.2020 | HealthCare Royalty Partners Raises $1.8 Billion | STAMFORD, Conn.--(BUSINESS WIRE)--HealthCare Royalty Partners, a global healthcare investment firm with $5.5 billion of cumulative capital commitments, today announced the closing on $1.83 billion for HealthCare Royalty Partners IV, L.P. an... |
| 17.02.2016 | HealthCare Royalty Trust takes aim at £200m IPO | |
| 13.02.2015 | How illuminating: Invuity raises $20M for its surgical tools that light up | Invuity’s small devices actually are quite complex. Much of the eight years was spent on designers perfecting their design of the company’s illuminating clips, which snap onto the retractors that snake through tissue. “It’s like trying to s... |
Show more